EV Biologics Develops Breakthrough Exosome-Based Therapeutics for Clinical Trials

TAMPA, FL – January 15, 2025 – EV Biologics Corp. (OTC PINK: YECO), a leading biotechnology company specializing in the development of stem cell-derived exosome-based therapeutics, is proud to announce advancements from its research and MSC exosome production. These developments pave the way for future clinical trials and new therapeutic applications targeting age-related and a range of chronic conditions.

Key Highlights of Recent Progress:

• Advanced Manufacturing Capabilities: EV Biologics has successfully achieved its next-generation mesenchymal stem cell (MSC) exosome-based product. The company has incorporated state-of-the-art biomanufacturing processes to ensure consistency, purity, and therapeutic potency.
• Global Clinical Trial Readiness: With preclinical validation underway, EV Biologics targets launching clinical trials focusing on regenerative medicine, longevity, and chronic disease management.
• Collaborative Research Initiatives: The company has partnered with leading research institutions and independent laboratories to enhance product validation, ensuring rigorous testing for molecular composition, bioactivity, and safety.

Daniel McKinney, CEO of EV Biologics, stated:

“Our mission is to revolutionize regenerative medicine by harnessing the power of biologically active nanotherapeutics. With our latest advancements, we are poised to provide transformative solutions for conditions such as frailty, chronic inflammation, and age-related decline. These products hold the potential to redefine healthcare by addressing the root causes of degeneration and promoting overall vitality.”

Expanding Market Potential

The global exosome therapeutics market is projected to grow significantly over the next decade, driven by advancements in personalized medicine and a rising demand for innovative treatments. EV Biologics is at the forefront of this rapidly evolving field, leveraging proprietary technologies to develop safe and effective biologics for diverse applications.

About EV Biologics

EV Biologics is a Wyoming-based biotechnology company focused on the development of stem cell-derived exosome-based therapeutics. The company is dedicated to advancing biomanufacturing, bioinformatics, and bioengineering solutions to optimize the therapeutic potential of extracellular vesicles. With a commitment to innovation, EV Biologics is addressing critical challenges in healthcare, including regenerative medicine, longevity, and chronic disease management.

Forward-Looking Statements

This news release contains forward-looking statements, particularly as related to, among other things, the business plans of the Company, statements relating to goals, plans and projections regarding the Company's financial position and business strategy. The words or phrases "plans," "would be," "will allow," "intends to," "may result," "are expected to," "will continue," "anticipates," "expects," "estimate," "project," "indicate," "could," "potentially," "should," "believe," "think," "considers" or similar expressions are intended to identify "forward-looking statements." These forward-looking statements fall within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Act of 1934 and are subject to the safe harbor created by these sections. Actual results could differ materially from those projected in the forward-looking statements as a result of a number of risks and uncertainties. Such forward-looking statements are based on current expectations, involve known and unknown risks, a reliance on third parties for information, transactions or orders that may be cancelled, and other factors that may cause our actual results, performance or achievements, or developments in our industry, to differ materially from the anticipated results, performance or achievements expressed or implied by such forward-looking statements. Factors that could cause actual results to differ materially from anticipated results include risks and uncertainties related to the fluctuation of local, regional, and global economic conditions, the performance of management and our employees, our ability to obtain financing, competition, general economic conditions and other factors that are detailed in our periodic reports and on documents we file from time to time with the Securities and Exchange Commission. Statements made herein are as of the date of this press release and should not be relied upon as of any subsequent date, and the Company specifically disclaims any obligation, to update any forward-looking statements to reflect occurrences, developments, unanticipated events or circumstances after the date of such statement.

YECO has 10.225 million shares issued and outstanding with a float of 1,016,375 shares.

www.evbiologics.com

Contact:

Dennis Burns

Investor Relations

dburns@nvestrain.com